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The aims of this study were to determine whether standard extracellular contrast agents of Gd(III) ions in combination with a
polymeric entity susceptible to hydrolytic degradation over a ﬁnite period of time, such as Hyaluronic Acid (HA), have suﬃcient
vascular residence time to obtain comparable vascular imaging to current conventional compounds and to obtain suﬃcient
data to show proof of concept that HA with Gd-DTPA ligands could be useful as vascular imaging agents. We assessed the dy-
namic relaxivity of the HA bound DTPA compounds using a custom-made phantom, as well as relaxation rates at 10.72MHz
with concentrations ranging between 0.09 and 7.96mM in phosphate-buﬀered saline. Linear dependences of static longitudinal
relaxation rate (R1) on concentration were found for most measured samples, and the HA samples continued to produce high
signal strength after 24 hours after injection into a dialysis cassette at 3T, showing superior dynamic relaxivity values compared to
conventional contrast media such as Gd-DTPA-BMA.
1.Introduction
Gadolinium chelates of small molecular weight are extracel-
lular space markers that improve tissue contrast by reducing
the longitudinal relaxation time and enhancing the diagnos-
tic eﬃcacy of MRI for the detection and characterization of
lesions and for the evaluation of perfusion and ﬂow-relat-
ed phenomena [1] and have been widely investigated struc-
turally [2] and clinically [3] as MRI contrast agents. MRI
blood-pool agents are often paramagnetic gadolinium che-
lates of high-molecular-weight polymers that are largely re-
tained within the intravascular space during the timespan of
an MRI scanning session [4].
It has been demonstrated that the relaxivity of a Gd(III)
complexwillincreaseuponslowingdownitsmoleculartum-
bling rates [5] and synthesizing more rigid molecules [6],
insofar as its water residence time is close to optimal [5]. Hy-
aluronic Acid (HA) is a natural polymer with a relatively stiﬀ
chain [7] and acid functional groups that can be utilized for
couplingGdcontrastagentsandhasbeeninvestigatedforuse
as a polymeric carrier for Gd complexes [8].
T h eﬁ n a lo b j e c t i v eo ft h i sp r o j e c tw a st od e v e l o pan e w
class of contrast agents for imaging the blood pool based on
HA-Gd complexes. The approach taken was to use standard
extracellular contrast agents of Gd(III) ions in combination
with a polymeric entity susceptible to hydrolytic degradation
over a ﬁnite period of time, such as HA. The end goal of this
study hence was to determine whether these MRI contrast
agents have suﬃcient vascular residence time to obtain com-
parable vascular imaging to the currently approved com-
pounds in use in Europe and the United States [9, 10]a n dt o
obtain suﬃcient data to show proof of concept that HA with
Gd-DTPAligandscouldbeusefulasvascularimagingagents.
In this exploratory study, the relaxivity of Gd-HA poly-
mer complexes at 10.72MHz was measured. We hypothesiz-
ed that the bound Gd ion would be free to inﬂuence the R1
of extracellular water molecules, yet the molecular size of
the Gd-polymer complex would have a molecular radius2 Radiology Research and Practice
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Figure 1: Scheme for mixed DTPA bisamide with free amine for coupling.
suﬃciently large to prevent diﬀusion through the vascular
wall.Thiswouldresultinbettervascularcontrastatrelatively
low Gd concentrations over an extended time period.
2. Methods
2.1. Preparation of Samples. We made DTPA dianhydride by
the procedure of Geraldes et al. in pyridine and acetic an-
hydride at 65◦C[ 11]. One can conceive of a number of ap-
proaches utilizing DTPA dianhydride with amines that result
in bound DTPA ligands to an HA backbone. One approach
is to couple ethylene diamine to the HA backbone by EDC
methods, then to react the dianhydride with the amine func-
tionalized HA. The second approach is ﬁrst to react a mo-
noamine with 1:1 stoichiometry with the dianhydride, then
to open the second anhydride with the free amine of ethyl-
enediamine bound to HA. A third approach is to vary the
stoichiometryofthediamineandthedianhydride,essentially
creating oligomeric DTPA ligands with free amine groups
that can then be coupled via EDC methods to the HA back-
bone. These approaches using the dianhydride eliminate the
deprotection steps of the Rappaport method [12], should re-
duce the amount of waste generated in the process, and more
readily lend themselves to scale-up (i.e., it is a “greener”
method). The samples used for imaging employed a 1:1
ratio of ethylene diamine to DTPA to make the DTPA amide
from the DPTA dianhydride, which was then coupled to HA
via the EDC/NHS method (Figures 1 and 2).Directinsertion
probe Mass Spectrometry with negative ionization of the
amine/DTPA oligomers was used to determine products in
a crude form.
2.1.1. Coupling of Gd-DTPA-Diamines to HA. Samples were
prepared using diamine functionalized DTPA and coupled
to HA solutions (0.5%) by way of standard EDC coupling
methods in Hepes buﬀer to arrive at DTPA functionalized
HA samples. Unhydrolyzed hyaluronic acid from Fluka with
ahigh-molecularweightwasusedtodeterminethefeasibility
of the project concept. The retention of high-molecular
weight HA derivatized with Gd complexes within a mem-
brane material with a known low-molecular weight cutoff
range was the expected result by virtue of the molecular
dimensions’ ﬁnal contrast agent. For example, 10mL of a
0.42% HA solution, 0.64mls 0.1M Hepes buﬀer at pH 7.0,
20mg EDC, and 20mg NHS were stirred for 30min at room
temperature, then 1.360mL of the bisamine DTPA product
(0.147M in amine) previously complexed with GdCl3 in
aqueous solution was added.
2.1.2. Determination of Complexed Gd Concentration and Re-
laxivities. Concentration of Gd in the ﬁnal HA complexes
used for longitudinal static relaxivity measurements was de-
termined photometrically by the method of Munshi and Dey
by ﬁrst ashing a sample in fuming nitric acid, followed by
a second ashing in concentrated HCl to dryness, then re-
dissolving the residue in distilled water volumetrically [13].
Aliquotsoftheﬁnalsolutionwereusedtodeterminethecon-
centration of free Gd3+ with pyridylazo resorcinol (PAR) to
determine the concentration of HA-DTPA-Gd complexes
from a calibration curve (Figure 3).
The concentration information was then used to dilute
samples to measure the longitudinal relaxation rates of the
complexes as a function of concentration. To perform these
measurements, dried quantities of the HA-Gd-DTPA end
samples were mixed into Dulbecco Phosphate Buﬀered Sa-
line in small tubes (2.1 × 8.0cm) to obtain ﬁnal concentra-
tions of 0.09, 0.12, 0.14, 0.17, 0.27, 0.50, 0.51, 0.62, 0.73,
0.95, 1.00, 1.26, 1.37, 1.54, 1.59, 1.70, 1.78, 2.21, 2.50, 2.53,
5.00, 6.32, and 7.96mM. Although limited in choice, these
concentrations were chosen so as to be in proximity of the
range for clinical relevance.
The ﬁnal prepared sample, called HWO-147, was an un-
hydrolysedhyaluronicacidDTPAcomplexwhoseconcentra-
tion of Gd-DTPA was about 10% by weight. To prepare the
samples for relaxation measurements, the desired amount
of sample was immersed in buﬀered saline after cutting the
freeze-dried samples with a razor blade on a clean surface.
They were then kept at 3◦C overnight to hydrate and stirred
the following morning to obtain a homogenous state. The
samples were kept at that temperature to minimize hydrol-
ysis, until immediately before the measurements the fol-
lowing day, at which time, the samples were heated to 39◦C,
the temperature inside the coil, using a water bath.
The instrument used to measure the T1 relaxation time
of all samples was a tabletop 10.72MHz NMR system (PR-
103 NMR Analyzer, PRAXIS, San Antonio, Tex, USA) de-
signed speciﬁcally for performing relaxometry measure-
ments on small samples.Radiology Research and Practice 3
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Figure 2: Hyaluronic acid repeat unit with amide bound diethylenediamine pentacetic acid. The Gd3+ ion is complexed with the bound
DTPA ligand to yield the imaging agent, which is then coupled to HA via standard carbodiimide coupling methods.
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Figure 3: Pyridylazo resorcinol calibration curve used to determine
Gd3+ concentrations in the samples tested for longitudinal relaxiv-
ity. The calibration curve was done using a solution of HA spiked
with GdCl3 to simulate the desired matrix for analysis.
The R1 relaxation rates were measured in volumes of
7mL (to receive the coil’s maximum signal), and static r1 re-
laxivities were determined by estimating the slope of the
relaxation-concentration ﬁtted curve for each type of solu-
tion.
2.2. Gd-HA Vascular Diﬀusion Imaging. In order to show
that the agent has a suﬃciently high blood-pool residence
time, a selected sample from the measured solutions was ex-
amined to see if the hydrodynamic size of the Gd-complex
polymer conjugate would be large enough to prevent imme-
diate diﬀusion through vascular wall-like conditions. Three
mL of HWO1-147 at a concentration of 2.5mM in 10mL of
PBS was injected into a 10,000 Dalton molecular weight cut-
oﬀ (MWCO) cassette (Slide-A-Lyzer, Thermo Fisher Scien-
tiﬁc, Waltham, Mass, USA). A second cassette was ﬁlled
with an extracellular MR contrast medium; Gd-DTPA-BMA
(Omniscan, GE Healthcare, Chalfont St. Giles, UK) for com-
parison. A phantom was then constructed by simultaneously
attaching two separate containers positioned horizontally to
the transmit/receive 3T head coil in the MRI system. The two
cassettes were each aﬃxed to the containers separately while
being immersed inside a 500mL beaker of Dulbecco Phos-
phate buﬀered saline; a volume that was large enough to
avoid any potential saturation eﬀects in the solution.
The phantoms were imaged simultaneously at 8 intervals
over a period of 24 hours at room temperature. The MR
image was acquired using a 3 Tesla MRI system (Magnetom
Trio, Siemens, Malvern, Pa, USA). A T1-weighted spin echo
inversion recovery sequence was used in which TE = 17ms,
TR = 750ms, NSA = 2, FOV = 200 × 120mm, slices = 5,
and the matrix size was 200 (FE) × 120 (PE). A TI of 300ms
was used to maximize the signal-to-noise ratio. In between
MRI scans, ﬂuid circulation was set up within each container
using stir bars to ensure a homogenous distribution of con-
trast in the containers.
2.3. Image Analysis. The obtained images in the phantom
experiment were intended to be analyzed visually, as a quali-
tative measure. However in order to obtain some degree of
quantiﬁable information on the signals, the characteristic4 Radiology Research and Practice
time of the signal drop for each type of contrast agent was
also estimated, that is, the time it takes for a given quantity to
drop to 1/e (37%) of its initial value. To estimate this quan-
tity, the center slices of each scan (8 in total) were selected,
the signal from an ROI placed at the center of each cassette
was consistently measured, and the background (in the con-
tainer) with the same area was then similarly recorded for all
8 points. We then plotted the signal intensity for a ﬁxed ROI
againsttime(witht = 0beingtheinjectionpoint)onsemilog
graph, and calculated the magnitude of the linearly ﬁtted
slope.
3. Results
The relaxivity value of the measured HA conjugates at con-
centrationsrangingfrom0.09mMto7.96mMandthecorre-
sponding standard error estimate using a commercial graph-
ing program (SigmaPlot v7.0, Systat Software Inc., Chicago,
Ill, USA) was 4.12 ± 0.07(mM·s)−1 for HWO-147. The un-
certainty of the relaxivity was calculated as the mean of the
absolute value of the diﬀerence between each data point and
the curve ﬁtted to the relaxation data (Figure 4).
As a comparison, the corresponding measured relaxivity
for Gd-DTPA-BMA was 4.90 ± 0.01(mM·s)−1. The manu-
facturer (Nycomed Ireland Ltd, IDA Industrial Estate, Car-
r i g t w o h i l l ,C c .C o r kI r e l a n d )r e p o r t sav a l u eo f4 . 6m M −1s−1
obtained at 10MHz ﬁeld strength at 37 degrees, and cur-
rent commercially available contrast agents have relaxivities
ranging from 4.5s−1mM−1 at 10.64MHz to 3.5s−1mM−1 at
85.14MHz [14].
Figure 5 shows the 24 hour progression of the phan-
tom after injection, with Gd-DTPA-BMA having extensively
leaked out of the cassette, while the HWO1-147 cassette has
relatively retained its contents.
The semi-log slope to the ﬁtted plots shown in Figure 6
was negative as expected, and in agreement with visual in-
spectionofT1images.Theplotsalsoindicatethatatthetime
of injection (t = 0), both cassette signals are of almost equal
strength, while at 400 minutes after injection, the retention
of the HWO1-147 signal strength can be clearly deduced by
the diﬀering slopes of the two samples. Their estimated
characteristic times were 706.93min for HWO1-147 and
429.23min for Gd-DTPA-BMA.
4. Discussion
In this exploratory study, we hypothesized that the eﬀective
hydrodynamicvolumeofthecontrastagentbylinkingastan-
dard Gd-DTPA contrast agent to HA decreased the diffusion
of the complex across a semipermeable dialysis membrane as
a model of the vascular walls. This was shown by the ability
of a dialysis membrane with a molecular weight cutoﬀ of
10kD to retain the coupled contrast agent for over twenty-
fourhours in an aqueous solution. Wen et al. have previously
used 10kD cassettes for the characterization and preliminary
evaluation of Gd3+-chelated poly(L-glutamic acid) polymers
for blood-pool imaging applications [15]. The MWCO must
be high enough to allow passage of blood proteins and nu-
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Figure 4: One of several experimental trials for determining the
relaxometry properties of HA-DTPA-Gd complexes. The Relaxivity
was calculated by estimating the slope of the relaxation rates (R) as
a function of concentration (mM).
trients, but low enough to reject the blood-pool agent. Our
results showed that the highest dynamic relaxivity was real-
ized in the oligomeric complexes of Gd coupled to the HA
backbone. Among these, sample HWO1-147 demonstrated
thecloseststaticrelaxivitytoGd-DTPA-BMA,albeitbeingan
unfractionated sample.
We used the procedure of Geraldes et al. to make DTPA
dianhydride in pyridine and acetic anhydride at 65◦C[ 11].
A signiﬁcant advantage from a clinical point of view of an
anhydride synthesis approach is that these ligands have only
three free carboxylates (and a charge of 3−)a tp h y s i o l o g i c a l
pH. When complexed with Gd3+, they result in a neutral
species.
Whereas an increase in the potential blood-pool resi-
dence time was observed in this study, it is anticipated that
the development of improved MRI blood-pool contrast
agents utilizing Hyaluronate polymers may lead to increased
utility of MRI methods for the assessment of tissue blood
perfusion, tissue blood volume, and quantitative microangi-
ography. The primary anticipated application of these re-
agents would be that the attachment of semirigid macro-
molecules to the Gd complexes would improve both the res-
idence time and signal enhancement in blood-pool MRI im-
aging.
Various polymeric MRI contrast agents, including hu-
manserumalbumin,polylysine,dendrimers,polyamide,and
grafted copolymers, have been synthesized and evaluated as
blood-pool imaging agents [15]. The clinical applications of
many current macromolecular contrast agents remain lim-
ited due to toxicity considerations [15]. By utilizing DTPA
coupling methods that would give a direct ester link of the
DTPA ligand to HA, the hydrolysis product of this adduct
would result in an HA molecule and free DTPA-Gd, which
is already an FDA approved product. Therefore with this
methodology we did not anticipate any signiﬁcant toxicity
from the DTPA-Gd complex over that of approved products.Radiology Research and Practice 5
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Figure 5: Magnetic resonance image montage of the progression of contrast media diﬀusion through a dialysis cassette at t = 0, 329, 407,
and 1489 minutes after injection, starting from top-left row, ending at bottom right. At 24 hours, the Gd DTPA-BMA (left ﬁxture) has leaked
out, while the HWO1-147 (right ﬁxture) is relatively well-retained inside its cassette.
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Figure 6: MRI intensity drop of Gd DTPA-BMA versus HWO1-
147 plotted against time. The semi-log plot is used to estimate the
characteristic time of the signal drop for Gd DTPA-BMA (pink
diamonds) versus HWO1-147 (dark circles), by calculating the
magnitude of the slope for each medium.
Furthermore, in order to fully investigate the eﬃcacy of
these contrast media, future studies should be conducted at
multiple frequencies to obtain and examine their NMRD
proﬁles, as they are a useful tool for studying the proton re-
laxation enhancement of MRI contrast agents [16].
5. Conclusion
In this study, we hypothesized that HA-Gd complexes have
the potential for extended lifetime in the blood pool, which
is potentially useful for magnetic resonance angiography ap-
plications over conventional Gd(III) chelates. We used static
and dynamic relaxivity measurements to examine whether
HA polymeric chelates would reside in the blood long
enough to allow for thorough MRI examinations, using a
semi-permeable dialysis membrane as a model of vascular
walls. The synthesized HA compounds showed superior dy-
namic relaxivity values compared to conventional contrast
media such as Gd-DTPA-BMA.
Abbreviations
BMA: Bismethylamide
DTPA: Diethylene triamine pentaacetic acid
EDC: 1-Ethyl-3-(3-Dimethylaminopro-
pyl)carbodiimide Hydrochloride
FE: Frequency Encoding
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Gd: Gadolinium
NHS: N-hydroxy succinimide
NMRD: Nuclear Magnetic Relaxation Dispersion
NSA: Number of Signal Averages
PE: Phase Encoding
R1: Longitudinal relaxation rate
TE: Time to Echo
TI: Inversion Time
TR: Repetition Time.
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